Hypomethylating agent based combinations in higher risk myelodysplastic syndrome

Abstract

For over a decade the hypomethylating agents (HMA) azacitidine and decitabine have been the mainstay of therapy for myelodysplastic syndrome (MDS). There is a critical need to improve frontline therapy, given that only up to half of high-risk MDS patients will respond to HMA therapy, and responses are short-lived. Currently, a key strategy has been to combine HMAs with other novel agents to improve patient outcomes. While synergy of agents is the goal of combination therapy, combinations often come at the cost of increased side effects that are often intolerable in this vulnerable population. The purpose of this review is to critically examine clinically relevant HMA combinations and discuss the future of MDS management.

Keywords:

• Myelodysplastic syndrome
• hypomethylating agents
• novel agents
• combination therapy
• disease management
• clinical trials

Disclosure statement

No conflict of interest was reported by Dr. Russell Lewis and Dr. Namrata Chandhok. Thomas Prebet received honoraria from Agios and Genentech.